Across TCGA pan-cancer cohorts, LINC01356 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated LINC01356 data layer compared with 22 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher LINC01356 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated LINC01356 expression acts as an unfavorable survival marker.

CESC are the cancer types where LINC01356 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	DFS	Median	All	0.146	0.740	<.001	12	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

Exploration

Same gene, other analysis: LINC01356 tumor-vs-normal RNA expression · all LINC01356 data types